The molecular and cellular origins of Hodgkin's disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed.

1. Distinctive patterns of marrow involvement by classic Hodgkin lymphoma are clues for diagnosis and subtyping.Virchows Archiv : an international journal of pathology · 2022
   Article
2. The Grey Zones of Classic Hodgkin Lymphoma.Cancers · 2022
   Review
3. NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.Biomedicines · 2018
   Review
4. Mechanisms underlying the association between obesity and Hodgkin lymphoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
   Review
5. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2016
   Article
6. The putative tumor suppressor Zc3h12d modulates toll-like receptor signaling in macrophages.Cellular signalling · 2012
   Article
7. Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.Clinical & developmental immunology · 2012
   Review
8. Nuclear factor-κB2 represses Sp1-mediated transcription at the CD99 promoter.Molecules and cells · 2011
   Article
9. Hodgkin disease and the role of the immune system.Pediatric hematology and oncology · 2011
   Review
10. Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-κB activity and miR-16-1*.Acta pharmacologica Sinica · 2011
    Article
11. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.Blood reviews · 2010
    Review
12. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.Molecular cancer · 2010
    Article
13. The intersection of Epstein-Barr virus with the germinal center.Journal of virology · 2009
    Article
14. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.The American journal of pathology · 2008
    Article
15. Genomic alterations in Hodgkin's lymphoma.International journal of hematology · 2006
    Review
16. Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.International journal of hematology · 2005
    Review
17. Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice.Cancer science · 2005
    Article
18. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells.The American journal of pathology · 2005
    Article
19. Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation.Oncogene · 2004
    Article
20. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells.The American journal of pathology · 2004
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as